Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the accord randomized trial

Diabetes Care

Volumn 37, Issue 6, 2014, Pages 1721-1728

  Margolis, Karen L ^a   O'Connor, Patrick J ^a   Morgan, Timothy M ^b   Buse, John B ^c   Cohen, Robert M ^d   Cushman, William C ^e   Cutler, Jeffrey A ^f   Evans, Gregory W ^b   Gerstein, Hertzel C ^g   Grimm Jr , Richard H ^h   Lipkin, Edward W ⁱ   Narayan, K M Venkat ^j   Riddle Jr , Matthew C ^k   Sood, Ajay ^l   Goff Jr , David C ^m  

^a HEALTHPARTNERS INSTITUTE   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CINCINNATI   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^g MCMASTER UNIVERSITY   (Canada)

^h Berman Center for Outcomes and Clinical Research   (United States)

ⁱ UNIVERSITY OF WASHINGTON   (United States)

^j EMORY UNIVERSITY   (United States)

^k OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^l CASE WESTERN RESERVE UNIVERSITY   (United States)

^m Global Health and Health Disparities   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FENOFIBRATE PLUS SIMVASTATIN; GHRELIN; GLITAZONE DERIVATIVE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; TRIACYLGLYCEROL; ANTILIPEMIC AGENT; FENOFIBRATE; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; SIMVASTATIN;

ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DISEASE DURATION; DYSLIPIDEMIA; ETHNICITY; FEMALE; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; COMPLICATION; DISEASE MANAGEMENT; DRUG EFFECTS; DYSLIPIDEMIAS; METABOLISM; MIDDLE AGED; MYOCARDIAL INFARCTION; PATHOPHYSIOLOGY; RISK REDUCTION; STROKE; TREATMENT OUTCOME;

ADULT; AGED; BLOOD GLUCOSE; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DISEASE MANAGEMENT; DYSLIPIDEMIAS; FEMALE; FENOFIBRATE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOLIPIDEMIC AGENTS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); RISK FACTORS; RISK REDUCTION BEHAVIOR; SIMVASTATIN; STROKE;

EID: 84901392373     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc13-2334     Document Type: Article

References (23)

1. Stamler J, Vaccaro O, Neaton JD,Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434-444
2. Kearney PM, Blackwell L, Collins R, et al.; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008;371:117-125
3. Turnbull F, Neal B, Algert C, et al.; Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood pressurelowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 2005;165:1410-1419
4. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-1589
5. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008;358:580-591
6. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348: 383-393
7. Goff DC Jr., Gerstein HC, Ginsberg HN, et al.; ACCORD Study Group. Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007;99 (Supplement 1):4i-20i
8. Buse JB, Bigger JT, Byington RP, et al.; ACCORD Study Group. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol 2007;99(12A):21i-33i
9. Ginsberg HN, Bonds DE, Lovato LC, et al.; ACCORD Study Group. Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007;99(12A):56i-67i
10. Cushman WC, GrimmRH Jr., Cutler JA, et al.; ACCORD Study Group. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. AmJ Cardiol 2007;99(12A):44i-55i
11. Gerstein HC, Miller ME, Genuth S, et al.; ACCORD Study Group. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 2011;364:818-828
12. Gerstein HC, Miller ME, Byington RP, et al.; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-2559
13. Cushman WC, Evans GW, Byington RP, et al.; ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010;362:1575-1585
14. Ginsberg HN, Elam MB, Lovato LC, et al.; ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362:1563-1574
15. Ismail-Beigi F, Craven T, Banerji MA, et al.; ACCORD trial group. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 2010;376: 419-430
16. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-713
17. Ismail-Beigi F, Craven TE, O'Connor PJ, et al.; ACCORD Study Group. Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients. Kidney Int 2012;81:586-594
18. BodenWE, Probstfield JL, Anderson T, et al.; AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011;365:2255-2267
19. Clofibrate and niacin in coronary heart disease. JAMA 1975;231:360-381
20. Scirica BM, Bhatt DL, Braunwald E, et al.; SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:1317-1326
21. White WB, Cannon CP, Heller SR, et al.; EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013;369:1327-1335
22. Benavente OR, Coffey CS, Conwit R, et al.; SPS3 Study Group. Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial [published correction appears in Lancet 2013;382:506]. Lancet 2013;382:507-515
23. Bangalore S, Kumar S, Lobach I, Messerli FH. Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations fromtraditional and Bayesian randomeffects meta-analyses of randomized trials. Circulation 2011;123:2799-2810